Profile: Zalicus Inc (ZLCS.OQ)

ZLCS.OQ on NASDAQ Stock Exchange Capital Market

0.64USD
4:00pm EDT
Price Change (% chg)

$0.16 (+32.64%)
Prev Close
$0.48
Open
$0.48
Day's High
$0.64
Day's Low
$0.48
Volume
904,057
Avg. Vol
125,042
52-wk High
$1.54
52-wk Low
$0.43

Search Stocks

Zalicus Inc. (Zalicus), incorporated in 2000 is a biopharmaceutical company that discovers and developsl treatments for patients suffering from pain and immuno-inflammatory diseases. The Company has a portfolio of clinical-stage product candidates targeting pain and immuno-inflammatory diseases and have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. It focuses on the discovery and development of selective ion channel modulators and its combination high throughput screening technology (cHTSTM) to discover new product candidates for its portfolio or for its collaborators in the areas of pain, inflammation, oncology and infectious disease.

On December 5, 2011, the Company initiated the first of multiple Phase 1 clinical trials to evaluate the pharmacokinetics and safety of several new formulations of Z160, a oral N-type calcium channel blocker for the treatment of neuropathic and inflammatory pain. On December 19, 2011, the Company initiated a Phase 1 clinical trial evaluating the safety and tolerability of Z944, a oral T-type calcium channel blocker for the treatment of inflammatory pain.

Synavive

The Company has one clinical stage product candidate, Synavive, targeting immuno-inflammatory diseases. Immuno-inflammatory diseases include rheumatoid arthritis, osteoarthritis, lupus (SLE), polymyalgia rheumatic, ulcerative colitis and Crohn’s disease. Synavive is designed to enhance the anti-inflammatory benefits of glucocorticoids, without associated dose-dependent side effects. It is being developed in an engineered formulation and contains the cardiovascular agent, dipyridamole, and a low dose of the glucocorticoid, prednisolone. In proof-of-concept clinical trials, Synavive demonstrated an anti-inflammatory effect in subjects with rheumatoid arthritis and osteoarthritis.

Ion Channel Programs

The N-type and T-type calcium channels in cells are important to the regulation of the body’s nervous and cardiovascular systems. The Company is developing compounds to treat pain and other diseases by selectively blocking ion channels in the neuronal cells responsible for pain signal transmission. Calcium channels are involved in a large number of normal physiological processes, including muscle contraction, hormone secretion, gene expression and electrical signaling in the nervous system.

Z160 and N-type Calcium Channel Program

The Company’s N-type calcium channel program is focused on developing drug candidates to treat chronic pain and its orally administered N-type calcium channel blockers, including Z160 (formerly referred to as NMED-160, have shown efficacy in multiple animal models of pain, and in the case of Z160, have been well tolerated in Phase I and Phase 2a clinical trials. Z160 is an N-type calcium channel blocker that has shown efficacy in multiple animal models of neuropathic and inflammatory pain, and has been well tolerated in Phase I and Phase 2a clinical trials in approximately 200 subjects.

Z944 and its T-type Calcium Channel Program

The Company’s T-type calcium channel program is focused on developing drug candidates to treat a variety of chronic pain conditions. Its orally administered T-type calcium channel blockers have shown efficacy in animal models of inflammatory pain. The distribution of T-type calcium channels found in brain, heart, endocrine cells and other tissues provides for the possibility of developing therapeutics for multiple indications, including treatment of pain or epilepsy.

Sodium Channel Program

The Company has generated a pipeline of preclinical agents shown to affect sodium channels. A number of these new compounds have been found to both reduce the excitability of neurons and to reverse pain hypersensitivity in animal models of acute and neuropathic pain. The Nav1.7 and Nav1.8 blocking compound Z212 acts by preferentially attenuating hyperexcitable neurons while sparing normally firing neurons.

Company Address

Zalicus Inc

Third Floor, 245 First St.
CAMBRIDGE   MA   02142
P: +1617.3017000
F: +1617.3017010

Search Stocks